<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644254</url>
  </required_header>
  <id_info>
    <org_study_id>ECLNI DPAC</org_study_id>
    <nct_id>NCT00644254</nct_id>
  </id_info>
  <brief_title>The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma</brief_title>
  <acronym>ECLNI DPAC</acronym>
  <official_title>The Prognostic Impact of Extracapsular Lymph Node Involvement (ECLNI) in Ductal Pancreatic Adenocarcinoma (DPAC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracapsular lymph node involvement (ECLNI) has been identified as a pathological variable
      associated with worse outcome in esophageal, gastric and colorectal cancer. No studies so far
      have studied its prognostic impact in ductal pancreatic adenocarcinoma (DPAC). The goal of
      the investigators is to determine the prognostic value of ECLNI in a prospective consecutive
      series of 145 patients with DPAC, who underwent resection of their primary tumor between 1998
      and 2005.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presence and extent of extracapsular lymph node involvement (ECLNI) will be scored by
      reviewing all original pathological slides.

      ECLNI is defined as metastatic adenocarcinoma extending through the nodal capsule into the
      perinodal fatty tissue.

      Observers: 1 experienced board-certified GI pathologist, blinded for follow-up results.

      Follow-up data are obtained by reviewing patients charts and by a telephone survey of the
      patient's GP/gastroenterologist in November 2007.

      Statistical analysis:

        -  Common closing date: 1/11/2007

        -  Kaplan-Meier survival analysis (Log-Rank, Wilcoxon)

        -  Cox logistic regression (uni/multivariate)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall cancer-specific survival</measure>
    <time_frame>11/2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)&amp; Correlation of ECLNI with other pathological variables</measure>
    <time_frame>11/2007</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">145</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Resected DPAC</arm_group_label>
    <description>145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic resection</intervention_name>
    <description>PPPD, Whipple, Total pancreatectomy or left pancreatectomy.</description>
    <arm_group_label>Resected DPAC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Resected ductal pancreatic adenocarcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DPAC

          -  Primary resection

        Exclusion Criteria:

          -  Positive section margins

          -  non DPAC, other tumor

          -  Postoperative mortality

          -  Neoadjuvant chemo/radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baki Topal, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Catholic University Leuven (KULeuven), Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Sergeant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadine Ectors, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Abdominal Surgery</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>July 6, 2009</last_update_submitted>
  <last_update_submitted_qc>July 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2009</last_update_posted>
  <keyword>Prognosis</keyword>
  <keyword>Extracapsular lymph node involvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

